Letter to the Editor of *Annals of Surgical Oncology* Concerning “The Landmark Series: Multimodality Therapy for Stage 3A Non-small Cell Lung Cancer”

Naveen Kumar, MS, MCh, Sandeep Bhoariwal, MS, MCh, and Sunil Kumar, MS, FACS

Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India

TO THE EDITOR

We read the article titled “The Landmark Series: Multimodality Therapy for Stage 3A Non-small Cell Lung Cancer” by Eby et al.¹ We thank and compliment the authors for a very nice review of two of the landmark trials for the management of stage 3A lung cancer.

However, we would like to draw your kind attention toward some of the errors in this article:

1. The CONSORT diagrams of both trials are the same. The CONSORT diagram which was mentioned for Southwest Oncology Group (SWOG) 8805 trial is actually for Intergroup trial (INT) 0139.²
2. In the results part of the INT 0139 trial review, the 5-year survival is wrongly mentioned for different subgroups. The survival which is mentioned here is the median survival. In the original trial description, the respective median and 5-year survivals were 34.4 months and 41.0% for T(any)N0, 26.4 months and 23.8% for T(any)N1–3 or unknown, and 7.9 months and 8.3% for no surgical resection.³

REFERENCES

1. Eby ME, Seder CW. The Landmark Series: multimodality therapy for stage 3A non-small Cell lung cancer. *Ann Surg Oncol*. 2020;27(8):3030–3036. <https://doi.org/10.1245/s10434-020-08553-z>.
2. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. *J Clin Oncol*. 1995;13(8):1880–1892. <https://doi.org/10.1200/jco.1995.13.8.1880>.
3. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. *Lancet*. 2009;374(9687):379–386. [https://doi.org/10.1016/S0140-6736\(09\)60737-6](https://doi.org/10.1016/S0140-6736(09)60737-6).

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.